TCA
IKT icon

Transcend Capital Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Transcend Capital Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.1K Buy
+16,107
New +$28.6K ﹤0.01% 716

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Transcend Capital Advisors's IKT Position: Q1 2026 in Review

Transcend Capital Advisors opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 16,107 shares worth $27.1K. The stake represents ﹤0.01% of the portfolio and ranks #716 among its holdings.

104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Transcend Capital Advisors held 16,107 shares of Inhibikase Therapeutics worth $27.1K as of Q1 2026.
  • Inhibikase Therapeutics was a new Transcend Capital Advisors position in Q1 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Transcend Capital Advisors's portfolio in Q1 2026, its #716 holding.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.